Skip to main content

High Costs, Negligible Benefits from Intellectual Property Provisions in FTAs

This is a preview of subscription content, access via your institution.

Notes

  1. 1.

    See http://ita.doc.gov/itac/committees/itac15.asp.

  2. 2.

    Australian Government, “Pharmaceutical Patents Review” 20, Draft Report (April 2013). Available at: http://www.ip-watch.org/weblog/wp-content/uploads/2013/04/Pharmaceutical-Patent-Review-Draft-Report.pdf.

  3. 3.

    See http://www.espicom.com/central-america-pharmaceutical-market.

  4. 4.

    http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/Total_World_Pharma_Market_Topline_metrics_2012.pdf.

  5. 5.

    Merck Sharp & Dohme Corp. v. Oficina Nacional de la Propiedad Industrial, Segunda Sala de la Cámara Civil y Comercial de la Corte de Apelación del Distrito Nacional, 31 May 2013.

  6. 6.

    Australian Government, op. cit., p. 32.

  7. 7.

    http://www.hktdc.com/info/mi/a/baus/en/1X0078EY/1/Business-Alert-%E2%80%93-US/Congress--Administration-Announce-Trade-Policy-Agreement.htm.

  8. 8.

    See Principles, para. 20.

  9. 9.

    See Brennan (2013).

Reference

  1. Hannah B, Rebecca D, Miriam H, Alix R (2013) A human rights approach to intellectual property and access to medicines (September 2013). Available at: http://media.wix.com/ugd/148599_c76ed6f7341fa426bc22f5ccf543ea04.pdf

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Carlos M. Correa.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Correa, C.M. High Costs, Negligible Benefits from Intellectual Property Provisions in FTAs. IIC 44, 902–905 (2013). https://doi.org/10.1007/s40319-013-0122-6

Download citation

Keywords

  • Trade Agreement
  • Dominican Republic
  • Free Trade Agreement
  • Patent Office
  • Marketing Approval